Abstract 1074
Background
Osimertinib (Tagresso) is recommended as an option for treating patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC whose disease has progressed after first-line TKIs. We compared OS and PFS in patients who received osimertinib treatment immediately after previous treatment with TKIs, and those who received osimertinib after their last cycle of chemotherapy.
Methods
This study enrolled a total of 2605 patients who were diagnosed with lung cancer between January 2013 and April 2017. Among these patients, there were 779 patients with inoperable EGFR-mutated NSCLC who had received TKIs as first-line therapy. Furthermore, 166 of these 779 patients who were resistant to TKIs had received re-biopsy. There were 71 patients who received osimertinib therapy for at least 2 weeks since March 2016.
Results
Demographics and clinical characteristics of the 71 patients are described in the table. Among these cases, 26 (36.6%) patients received osimertinib as 2nd-line therapy after first-line TKI therapy. Seventeen (23.9%) patients received osimertinib as 3rd-line therapy, and 28 (39.4%) patients received osimertinib in > = 4th-line setting. The median PFS in patients as 2nd-line therapy was 11.9 months and that was 17.3 months as 3rd-line therapy. The median PFS in patients as > = 4th-line therapy was 9.3 months. Among the 71 patients, there were 34 (47.9%) patients who received it after previous chemotherapy (Group A), and 37 patients (52.1%) who received osimertinib immediately after previous TKI therapy (Group B). The median PFS for Group A and Group B patients was 12.8 months and 11.0 months, respectively (p = 0.306). A higher percentage of patients in Group B had progressive disease (8 cases, 21.6%) compared to Group A (2 case, 5.9% ; χ2 = 0.08). Besides, obesity patients (BMI > = 27) had trend of shorter PFS with osimertinib therapy. (8.4 months vs. 12.6 months, P = 0.05).
Conclusions
Our data suggested that T790M-mutated NSCLC patients may have a better response, and longer PFS when treated with osimertinib therapy after previous chemotherapy compared to after previous TKI treatment. Due to the small sample size, our data need to be updated and need further re-analysis.
Clinical trial identification
Legal entity responsible for the study
Chien-Hao Lai; Chin-Chou Wang.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract